
-
Relmada Therapeutics NasdaqGS:RLMD Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Location: 2222 Ponce de Leon Blvd., Coral Gables, FL, 33134, United States | Website: https://www.relmada.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-3.107M
Cash
27.06M
Avg Qtr Burn
-14.2M
Short % of Float
4.97%
Insider Ownership
17.03%
Institutional Own.
33.47%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NDV-01 Details Non-muscle invasive bladder cancer | Phase 2 Update | |
Sepranolone Details Tourette syndrome | Phase 2 Initiation | |
Sepranolone Details Prader Willi syndrome | Phase 2 Initiation | |
REL-P11 Details Obesity, Metabolic disorder | Phase 1 Update | |
Psilocybin (REL-P11) Details Obesity, Metabolic disorder | Phase 1 Initiation | |
REL-1017 Details Major depressive disorder, Mental health | Failed Discontinued |